US 12,275,961 B2
Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation
Xiaolei Tang, Loma Linda, CA (US); David J. Baylink, Redlands, CA (US); K.-H. William Lau, Redlands, CA (US); and Michael Walter, Loma Linda, CA (US)
Assigned to LOMA LINDA UNIVERSITY, Loma Linda, CA (US)
Filed by LOMA LINDA UNIVERSITY, Loma Linda, CA (US)
Filed on Jan. 16, 2020, as Appl. No. 16/744,296.
Application 16/744,296 is a continuation of application No. 15/550,501, granted, now 10,577,669, previously published as PCT/US2016/017610, filed on Feb. 11, 2016.
Claims priority of provisional application 62/115,040, filed on Feb. 11, 2015.
Prior Publication US 2020/0149121 A1, May 14, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0784 (2010.01); A61K 38/44 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C12N 9/02 (2006.01); C12P 19/34 (2006.01)
CPC C12N 9/0008 (2013.01) [A61K 38/44 (2013.01); A61K 39/4615 (2023.05); A61K 39/4621 (2023.05); A61K 39/4622 (2023.05); A61K 39/46433 (2023.05); A61K 39/464454 (2023.05); A61K 48/00 (2013.01); C12N 9/0073 (2013.01); C12P 19/34 (2013.01); C12Y 102/01036 (2013.01); C12Y 114/13013 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05)] 10 Claims
 
1. A gene-modified dendritic cell for treating a gastro-intestinal inflammatory disease, the gene-modified dendritic cell overexpressing a cytochrome p450 family 27 subfamily B polypeptide 1 (CYP27B1) gene encoding 1-alpha-hydroxylase and overexpressing an aldehyde dehydrogenase 1 family member A2 (ALDH1a2) gene encoding retinaldehyde dehydrogenase 2 (RALDH2), wherein the gene-modified dendritic cell is engineered to constitutively overexpress the 1-alpha-hydroxylase.